ADMA Biologics Inc (ADMA)
ADMA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/0001140361-26-006815-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ADMA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001368514 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $510.2M |
| Net income | $146.9M |
| Operating income | $191.4M |
| Net margin | 28.8% |
| Operating margin | 37.5% |
| Revenue growth | +19.6% |
| Cash | $87.6M |
| Total assets | $624.2M |
| P/E (computed) | 20.3× |
| P/S (computed) | 5.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $124.6M cash; operating cash flow $35.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 221,854,389 (2026-10-30); 237,997,765 a year earlier; 225,967,668 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Stamford, Connecticut, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $468K, sold $1.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $141.1M | $49.9M | $17.4M | $124.6M | $195.9M | $519.2M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $124.4M | $37.8M | $29.5M | $136.0M | $196.6M | $512.3M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $114.5M | $45.3M | $58.2M | $138.2M | $196.9M | $509.9M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $139.2M | $49.4M | $35.6M | $87.6M | $72.1M | $510.2M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $134.2M | $36.4M | $13.3M | $61.4M | $72.4M | $488.6M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $122.0M | $34.2M | $21.1M | $90.3M | No debt tags | $474.2M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $114.8M | $26.9M | -$19.7M | $71.6M | No debt tags | $459.4M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $117.5M | $111.9M | $50.2M | $103.1M | $72.3M | $426.5M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2022-12-07 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-15 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.5% |
| 1 month | +32.7% |
| 3 months | +45.4% |
| Year to date | -25.0% |
| 1 year | -12.9% |
| From 52-week high | -32.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VCEL | Vericel Corporation | $57.48 | +0.91% | $2.9B |
| DNLI | Denali Therapeutics Inc. | $18.08 | -3.52% | $2.9B |
| IOVA | Iovance Biotherapeutics Inc. | $7.55 | -2.71% | $3.5B |
| RLAY | Relay Therapeutics Inc. | $17.27 | -4.53% | $3.8B |
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| BEAM | Beam Therapeutics Inc. | $20.94 | -8.28% | $2.2B |
| REPL | Replimune Group Inc. | $21.41 | -2.19% | $2.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier